Aurobindo Pharma’s arm recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths

16 Dec 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths in the US market. The New Jersey-based firm is recalling the product due to 'GMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit. The company initiated the Class II recall on November 7, 2024. Cinacalcet tablets are used to treat hyperparathyroidism. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1172.30 -7.95 (-0.67%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×